We used certain TMZ concentrations to treat these glioma cells (U87‐EGFRvIII 500 μM/72 h, GSC464 200 μM/72 h, SNB19 100 μM/72 h, and GSC267 100 μM/72 h, based on the IC50 of temozolomide); the results of the CCK‐8 assay showed that overexpression of Slug prevented the IFI30 knockdown‐induced enhancement of the efficacy of TMZ and increased the cell survival rate. Here, IFI30 is linked to central nervous system cancer.